In the effort to discover a cure for CF, there are gaps between basic science and clinical research.  Translational research intends to bridge such gaps by encompassing early stage drug discovery, including target validation, assay development, library screening, lead identification, lead optimization, and candidate selection.

Because of the small CF patient population, translational research for CF has been too risky for ‘for-profit’ corporations.   Therefore, it has been underfunded, and has been a speed bump for CF drug development.  Removing this speed bump may reduce the risk, attract the interests of big pharma, and accelerate the development of new CF therapeutics. Flatley Discovery Lab will focus on translational research in the development of new CF treatments.

To accomplish its risk reduction strategy, Flatley Discovery Lab conducts intense early stage drug screening campaigns with the most advanced technologies available in the CF community.

Flatley Discovery Lab’s strategy to reduce development risk also includes focusing on identifying high quality leads.  The not-for-profit biotech model makes it possible for Flatley Discovery Lab to function in fundamentally different ways than a for-profit company.  As a not-for-profit organization, Flatley Discovery Lab is not constrained by profit or IP issues, and is free to examine non-patentable or unprofitable approaches to treating CF.  In addition, not-for-profit status allows Flatley Discovery Lab to enter more productive agreements and alliances that are not hindered by endless negotiations.

With these unique business strategies and the advantages of not-for-profit business model, Flatley Discovery Lab creates focus, expertise, compound access, and deal flow, and is able to efficiently and effectively move compounds through translational research and produce quality clinical candidates.